Saleem Muhammad, Khan Sajjad Ali, Suchal Zafar Aleem, Ram Nanik
Muhammad Saleem, FCPS, Fellow- Section of Endocrinology, Department of medicine, Aga Khan University Hospital, Karachi, Pakistan.
Sajjad Ali Khan, FCPS, Fellow- Section of Endocrinology and Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan.
Pak J Med Sci. 2022 May-Jun;38(5):1255-1259. doi: 10.12669/pjms.38.5.5034.
To evaluate the clinical and biochemical effects of (SGLT2) inhibitors as a fourth oral anti-diabetic drug in patients with Type-2 diabetes mellitus (T2DM).
In a tertiary hospital in Karachi, Pakistan, a retrospective assessment of patient medical records was conducted from January 1, 2017 to December 31, 2020.A total of one hundred patients (mean age [Standard Deviation]: 53.8 [9.63] years) with poorly controlled T2DM were included. Data was collected before the SGLT-2 inhibitor was added, as well as three and six months after the medicine was started. Weight, BMI, blood pressure (BP), HbA1c, SGPT, and Creatinine were measured at the start and during the study.
There was a significant reduction in HbA1c (p-value < 0.001) with a mean reduction (MR) of 0.81+1.02% at three months and 1.07+1.11% at six months. A mean weight reduction (p-value < 0.001) of 1.83+2.32 kg at three months and 4.02+6.04 kg at 6 months, respectively, was recorded. A mean BMI reduction of 0.69+0.95 kgm-2 at three months and 2.13+3.41 kgm-2 at six months of follow up, respectively were recorded. A systolic blood pressure (SBP) also showed a significant reduction (p-value < 0.05) with a MR of 5.9+15.76 mmHg at three months and 6.37+18.33 mmHg at 6 months, respectively. Non-significant variation in creatinine and SGPT was also noted.
SGLT-2 is an effective oral anti-diabetic medicine that can help individuals with diabetes who are currently using glucose-lowering oral anti-diabetic medications. These medications can help diabetic patients stick to their regimen.
评估钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂作为2型糖尿病（T2DM）患者的第四种口服抗糖尿病药物的临床和生化效果。
在巴基斯坦卡拉奇的一家三级医院，对2017年1月1日至2020年12月31日期间患者的病历进行回顾性评估。共纳入100例T2DM控制不佳的患者（平均年龄[标准差]：53.8[9.63]岁）。在添加SGLT-2抑制剂之前以及开始用药后的3个月和6个月收集数据。在研究开始时和研究期间测量体重、体重指数（BMI）、血压（BP）、糖化血红蛋白（HbA1c）、谷丙转氨酶（SGPT）和肌酐。
糖化血红蛋白显著降低（p值<0.001），3个月时平均降低（MR）0.81+1.02%，6个月时平均降低1.07+1.11%。记录到3个月时平均体重减轻（p值<0.001）1.83+2.32kg，6个月时平均体重减轻4.02+6.04kg。随访3个月和6个月时，平均BMI分别降低0.69+0.95kg/m²和2.13+3.41kg/m²。收缩压（SBP）也显著降低（p值<0.05），3个月时MR为5.9+15.76mmHg，6个月时MR为6.37+18.33mmHg。肌酐和SGPT也有非显著性变化。
SGLT-2是一种有效的口服抗糖尿病药物，可帮助目前正在使用降糖口服抗糖尿病药物的糖尿病患者。这些药物可帮助糖尿病患者坚持治疗方案。
